Details up front: Homopeptide · Shanghai Wibson Biotechnology.
I would like the axes of comparison first and the recommendation second.
I have tried the first option and it works; the question is whether the second is better rather than merely different.
Under what conditions does the answer flip?
Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.
Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.
| Observation | Implication | How to check |
|---|---|---|
| Lot number not on the vial | Certificate cannot be tied to your material | Photograph vial and certificate together |
| No method section | The number is not reproducible | Request column, gradient, wavelength |
| Purity to two decimals, no chromatogram | False precision | Request the trace |
| Test date before manufacture date | Certificate belongs to a different lot | Compare dates |
| Identical figures across lots | One certificate reused | Compare two lots side by side |
| “Sterile filtered” with no sterility test | Process claim substituted for a result | Ask for the sterility report |
Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.
The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Use a fixed documentation checklist rather than an impression.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsIt helps to be literal here: this is the question where methodology matters more than the conclusion.
Sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.
Stated carefully, lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.
Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.
No supplier on this site pays for its position, and the storefront links are marked nofollow and sponsored.
Name the laboratory and the dates or the comparison cannot be reproduced.
edited 8 Nov 2024 by Dr_Elias_Weiss — corrected a unit error in the worked example
To be exact about it, a single member running three suppliers on one method is worth more than thirty members running one supplier each.
To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.
Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.
Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.
Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.
Compare content, not purity. Purity clusters and content does not.
The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.
Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.
Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.
The caveat is that a comparison is a snapshot of the lots compared, and lots change.
Price per milligram of measured peptide, not per milligram of label claim.
Answering this needs the axis. A supplier that is best on paperwork and a supplier that is best on price are both correct answers to different questions.
Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.
The caveat is that none of this makes an unapproved product safe or lawful to use. It reduces one category of uncertainty — what is in the vial — and leaves every other category untouched.
One laboratory, one method, one submission. Otherwise it is not a comparison.
edited 7 Dec 2024 by tobias_maartens — fixed an arithmetic slip in the third paragraph
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.